To compare changes in signal intensity (SI) ratios of the dentate nucleus (DN) and the globus pallidus (GP) to those of other structures on unenhanced T1-weighted magnetic resonance (MR) images between linear and macrocyclic gadolinium-based contrast agents (GBCAs).
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Radbruch et al I nvestigators in three recently published studies (Kanda et al [1] [2014], Errante et al [2] , and Kanda et al [3] [2015]) reported increased signal intensities (SIs) in the dentate nucleus (DN) on unenhanced T1-weighted magnetic resonance (MR) images after serial application of gadolinium-based contrast agent (GBCA) for contrast materialenhanced MR imaging. The authors of these studies suggested a deposition of gadolinium in the DN as a possible cause of the increased SI on unenhanced T1-weighted images.
Free gadolinium is highly toxic, which is why it needs to be bound to a ligand for its use as a contrast agent (4) . Hence, one mechanism underlying the potential toxic effects of GBCAs is the release of gadolinium ions (Gd 3+ ) from the complex and its deposition in tissues. This potential release of Gd 3+ ions depends on the stability of the GBCA in a biologic environment, the physicochemical properties, and the chemical structure of the gadolinium complex. In this respect, commercially available gadolinium complexes can be divided into two major classes: linear and macrocyclic complexes (Fig 1) (5, 6) . Several investigators have found an increased release of Gd 3+ ion in vitro from linear GBCAs compared with macrocyclic GBCAs, as well as a higher deposition rate in some tissues in vivo Implication for Patient Care n Even though no clinical implications can be drawn from the reported hyperintensities in the DN and the GP, the findings are worrisome and should be taken into account when deciding whether to use gadopentetate dimeglumine.
Advances in Knowledge
n Increased signal intensities (SIs) in the dentate nucleus (DN) and globus pallidus (GP) on unenhanced T1-weighted images are related to the serial application of the linear gadolinium-based contrast agent (GBCA) gadopentetate dimeglumine (P , .001 for both DN and GP).
n No significant SI increase could be demonstrated after serial applications of the macrocyclic GBCA gadoterate meglumine (P = .680 for DN, P = .538 for GP).
n The SI increase of the DN depends on the accumulated dose of the applied GBCA in the gadopentetate dimeglumine group (P = .001). Abbreviations: CI = confidence interval CSF = cerebrospinal fluid DN = dentate nucleus eGFR = estimated glomerular filtration rate GBCA = gadolinium-based contrast agent GP = globus pallidus SI = signal intensity (6,7). These findings suggest that the occurrence of increased SI in the DN after serial application of contrast agents may result from a local Gd 3+ ion deposition and depend on the class of GBCA used.
In Kanda et al (3) , the authors provide evidence that SI increase in the DN on unenhanced T1-weighted MR images is associated with the previous administration of the linear GBCA gadopentetate dimeglumine (Magnevist; Bayer), but not with the macrocyclic GBCA gadoteridol (ProHance; Bracco Spa, Milano, Italy). However, the statistical power of this study was limited because of the low number of included patients with proven hyperintensity on unenhanced T1-weighted images in the DN (nine patients) and the absence of a longitudinal comparison of SIs in patients who received high numbers of previous GBCA administrations.
In the current study, we investigated two large patient cohorts who underwent at least six serial MR imaging examinations to compare changes in SI ratios of the DN and the globus pallidus (GP) to those of other structures on unenhanced T1-weighted MR images between linear and macrocyclic GBCAs.
Materials and Methods
This retrospective study was financially supported by Guerbet. The authors of this study had full control of the data and the information submitted for publication.
Patients
The study was approved by the ethical committee of the University of Heidelberg (reference no. S-324/2014). Because of the retrospective character of the study, the ethical committee did not require any written informed consent. All patients had given consent to the use of their image data at the time of the examination.
Our in-house radiologic information system was screened for consecutive patients until two groups of 50 consecutive patients were identified who underwent at least six consecutive MR imaging examinations by using exclusively linear GBCAs (gadopentetate dimeglumine, Magnevist; Bayer) or macrocyclic GBCAs (gadoterate meglumine, Dotarem; Guerbet) and who fulfilled inclusion criteria and did not fulfill the exclusion criteria.
Inclusion criteria were the following: (a) at least six consecutive gadolinium-enhanced MR imaging examinations were performed with exclusively linear GBCAs or exclusively macrocyclic GBCAs as the contrast agent and (b) all of those consecutive MR imaging examinations were performed exclusively in our department. Included MR imaging examinations did not have to be the first examinations in which GBCAs were used, and prior gadolinium-enhanced examinations might have been performed at NEURORADIOLOGY: Gadolinium Retention in the Dentate Nucleus and Globus Pallidus Radbruch et al 
Data Analysis
Eighty-one consecutively examined patients who underwent at least six consecutive MR imaging examinations with linear GBCAs and 64 patients who underwent at least six examinations with macrocyclic GBCAs were assessed to identify 50 patients in each group who fulfilled the inclusion and exclusion criteria ( The different time periods in which the data of the different groups were collected are explained by the fact that both GBCAs were preponderantly used at different time periods in our clinic.
For all included patients, age, sex, diagnosis, liver function, and eGFR were evaluated by means of chart review (Table 2 ). Diagnosis was further specified as (a) glioblastoma World Health Organization, or WHO, grade IV, (b) glioma WHO grade I-III, (c) brain tumor other than glioma WHO grade I-IV, such as cerebral lymphoma, and (d) no tumor. For all included patients, it was further assessed whether molecularly targeted therapy (eg, bevacizumab) or alkylating antineoplastic chemotherapy were applied. Furthermore, it was assessed whether patients were treated with whole-brain or tumor-selective brain radiation. Renal function was evaluated by calculating Table 1 Exclusion Criteria
Parameter
Macrocyclic GBCA Group Linear GBCA Group 
MR Imaging Protocol
MR imaging was performed with a 3-T imaging unit (Trio and/or Verio; Siemens, Erlangen, Germany) or a 1.5-T imaging unit (Symphony; Siemens). The standard MR imaging protocol included an axial T1-weighted spin-echo sequence (repetition time msec/echo time msec, 500/14; section thickness, 6 mm) or a T1-weighted three-dimensional magnetization-prepared rapid gradient-echo sequence (1740/3.45; section thickness, 1.0 mm; field of view, 250 mm) before and after GBCA injection, T2-weighted imaging (4890/85; section thickness, 5 mm; field of view, 230 mm), and a fluid-attenuated inversion-recovery sequence (8500/85; inversion time, 2400 msec; the eGFR from a recent blood sample, on the basis of the Chronic Kidney Disease Epidemiology Collaboration formula. All patients with an eGFR less than 60 mL/min per 1.73 m 2 were excluded. For the included patients, it was assessed whether the eGFR was (a) less than 90 mL/min per 1.73 m 2 or (b) more than 90 mL/min per 1.73 m 2 . Abnormal liver function was defined by abnormal serum concentrations of alanine aminotransferase, g-glutamyl transpeptidase, or aspartate aminotransferase. Since the applied linear GBCA and macrocyclic GBCA are both eliminated exclusively by the kidneys, patients with abnormal liver function were not excluded from our study. Finally, the mean interval between GBCA administrations was calculated by dividing the time (in weeks) between the first and last MR imaging examinations section thickness, 5 mm; and field of view, 230 mm).
Because of the introduction of perfusion-weighted MR imaging in the tumor protocol with a prebolus design (8) after 2010, the applied dose of GBCA differed between groups. There was an exclusive application of a standardized single dose of 15-20 mL in the linear GBCA group and a double injection of GBCA in most of the patients with tumors in the macrocyclic GBCA group. The injected dose of macrocyclic GBCA was adapted to 0.1 mmol per kilogram of the patient's body weight. These different application schemes resulted in a substantially larger dose of the macrocyclic GBCA per MR imaging session (mean dose 6 standard deviation, 27.07 mL 6 6.86 per MR imaging examination) compared with the linear GBCA (19.62 mL 6 1.74 per MR imaging examination).
Image Analysis
Image analysis was conducted as described previously by Kanda et al (1,3), but we added the cerebrospinal fluid (CSF) as an additional validator. Thus, the DN SI was compared with that of three structures: the pons, CSF, and cerebellum. All images were reviewed on our picture archiving and communication system. A region of interest was drawn on the unenhanced T1-weighted images on the central pons, the CSF of the fourth ventricle, the cerebellum next to the DNs, and the right and left DNs. To assess the GP, regions of interest were drawn on the GP, as well as on the thalamus. To guarantee a correct placement of the region of interest, T2-weighted images were additionally used for the identification of the DN. The image analysis was performed by a radiologist (A.R.) with 6 years of experience, who was blinded to the clinical data. In contrast to Kanda et al (1, 3) , who assessed only one DN, GP, and thalamus, we calculated the mean of the left and the right GP, cerebellum, and DN to improve accuracy.
Statistical Analysis
Analyses were conducted by using the R language and environment for statistical computing (version 3.1.0, R Foundation for Statistical Computing, Vienna, Austria), and the a priori significance level was set to P less than .05. One-sample t tests were used to examine whether the mean SI ratio differences between the last and first examination in each patient group were different from 0, and JeffreysZellner-Siow Bayes factors were computed to quantify the strength of evidence in favor of the null hypothesis (no difference from 0) or the alternative hypothesis (difference from 0) (9) . An independent-sample t test was used to test whether the differences between the two patient groups were statistically significant. These analyses were conducted for the DN-to-pons ratio, the DN-to-CSF ratio, the DN-tocerebellum ratio, and the GP-to-thalamus ratio. For the DN-to-pons ratio, which has mostly been used in previous studies (1,2), additional analyses were conducted: Regression analyses were used to examine whether the differences between groups remained significant after accounting for potential confounding variables. Correlation analyses were used to test whether the number of contrast-enhanced MR imaging examinations, the mean interval between GBCA administrations, and the accumulated dose of GBCA had a different influence in each patient group, supplementing the analysis with Jeffreys-Zellner-Siow Bayes factors to quantify the strength of evidence (10) . Since the sequences used for T1-weighted MR imaging examinations differed in the linear GBCA group (31 magnetization-prepared rapid gradient-echo sequences and 19 spin-echo sequences), a subgroup analysis with an independent sample t test was performed to examine whether the sequences had an influence on the SI ratio difference.
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Results
The characteristics of each group are described in Table 2 , and the distribution of SI ratio differences for the DN-to-pons ratio per group are displayed in Figure 2 .
In the linear GBCA group, the mean DN-to-pons SI ratio difference of 0.0407 6 0.0398 between the last and first examinations was significantly larger than 0 (P ,. 001, 95% confidence interval [CI]: 0.0294, 0.0520), and the Bayes factor of 4 214 210 indicated strong support for the alternative hypothesis (difference from 0). In the macrocyclic GBCA group, the mean SI ratio difference of 0.0016 6 0.0266 did not show a significant deviation from 0 (P = .680, 95% CI: 20.0060, 0.0091), and the Bayes factor of 0.17 indicated positive evidence for the null hypothesis (no difference from 0).
The mean SI ratio difference was significantly larger in the linear GBCA group than in the macrocyclic GBCA group (P , .001, 95% CI: 0.0257, 0.0526) (Fig 3) . The standardized difference between the two groups was d = 1.16, which corresponded to a large effect size. All previous results could be replicated by using the nonparametric equivalents (Wilcoxon signed rank and Mann-Whitney U tests).
When repeating the analyses for the DN-to-cerebellum ratio and the DN-to-CSF ratio, the results were comparable, with a difference that was significantly larger than 0 in the linear GBCA group (cerebellum, P , .001, Bayes factor = 4070; CSF, P , .001, Bayes factor = 2078), no significant difference from 0 in the macrocyclic GBCA group (cerebellum, P = .213, Bayes factor = 0.32; CSF, P = .143, Bayes factor = 0.43), and a significantly larger SI ratio difference in the linear GBCA group than in the macrocyclic GBCA group (cerebellum, P , .001, d = 0.74; CSF, P , .001, d = 0.89). However, the differences were strongest for the DN-to-pons ratio, which has been used both by Kanda et al (1) and Errante et al (2) .
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Radbruch et al The GP-to-thalamus ratio also showed comparable results. Consistent with Kanda et al (1) , the GP-tothalamus ratio difference was significantly larger than 0 in the linear GBCA group (0.0287 6 0.0275; 95% CI: 0.0209, 0.0365; P , .001; Bayes factor = 6 661 191). In line with the results for the DN, the ratio difference was not significantly different from 0 in the macrocyclic GBCA group (0.0031 6 0.0354; 95% CI: 20.0069, 0.0132; P = .538; Bayes factor = 0.18). Finally, the difference was significantly larger in the linear GBCA group than in the macrocyclic GBCA group (P , .001, d = 0.81).
To control for the possibility that the difference between the two groups was due to other confounding variables, a linear regression analysis by using the DN-to-pons SI ratio difference as a criterion was performed. The results are summarized in Table 3 . Even when controlling for a large number of variables, the effect of contrast agent on SI ratio difference remained highly significant (P , .001). The control variables sex, age, liver function, kidney function, diagnosis, chemotherapy, and radiation therapy did not have a significant influence on the SI ratio difference. The effect of contrast agent on SI ratio difference also remained highly significant (P , .001) when controlling for the number of contrast-enhanced MR imaging examinations, the accumulated dose of GBCA, and the mean interval between GBCA administrations in separate regression analyses.
The mean interval between GBCA administrations was not a predictor of a significant increase of the SI ratio difference, whereas both the number of contrast-enhanced MR imaging examinations and the accumulated dose of GBCA were. In additional analyses, we examined whether the respective correlation with the SI ratio difference was comparable for the linear GBCA group and the macrocyclic GBCA group or if it differed between groups.
In the linear GBCA group, the number of enhanced MR imaging examinations was positively related to an increase of the SI ratio difference (r = 0.422, P = .002), the Bayes factor of 11 indicating positive evidence for the alternative hypothesis (correlation different from 0). In the macrocyclic GBCA group, no significant relationship was found (r = 0.015, P = .917), with the Bayes factor of 0.11 indicating positive support for the null hypothesis (no correlation). A test for independent correlations indicated that the correlation in the linear GBCA group was significantly larger than the correlation in the macrocyclic GBCA group (P = .035).
Radbruch et al The pattern of results was comparable when analyzing the relationship between accumulated dose of GBCA and SI ratio difference, with a significant correlation (r = 0.444, P = .001) and positive evidence for it (Bayes factor = 20) in the linear GBCA group but no significant correlation (r = 0.006, P = .967) and positive evidence for the null hypothesis (Bayes factor = 0.11) in the macrocyclic GBCA group. Likewise, these correlations differed significantly (P = .022). As in the overall regression analysis, the correlation between mean interval of GBCA administrations and SI ratio difference was not significant in both groups (linear GBCA group, r = 0.096, P = .506, Bayes factor = 0.14; macrocyclic GBCA group, r = 20.107, P = .460, Bayes factor = 0.15). Finally, the independent-sample t test used to compare the T1-weighted sequences applied (magnetization-prepared rapid gradient-echo and spinecho) in the linear GBCA group indicated that the sequence did not have a significant influence on the SI ratio difference (P = .770). Figure 4 shows a typical finding before and after six administrations of a macrocyclic or linear GBCA.
Discussion
In this study, we found an increased SI in the DN and GP on unenhanced T1-weighted images after serial applications of the linear GBCA gadopentetate dimeglumine, while no significant SI increase could be demonstrated for the macrocyclic GBCA gadoterate meglumine. Notably, this difference between the contrast agents was found, despite the fact that a substantially larger dose of contrast agent per MR imaging session was used in the macrocyclic GBCA group compared with the linear GBCA group. Furthermore, depending on the accumulated dose of GBCA, an increase of SI could be shown in the linear GBCA group, while no increase was found in the macrocyclic GBCA group.
These results confirm the findings of Kanda et al (3) for the applied linear GBCA gadopentetate dimeglumine and add further evidence that macrocyclic GBCA such as the assessed gadoterate meglumine does not cause an SI increase in the DN on unenhanced T1-weighted images; this latter finding was reported by Kanda et al (3) for the macrocyclic GBCA gadoteridol, but it is new for the GP.
Currently, it has not been proven that the SI increase in the DN or GP in patients with serial MR imaging examinations is caused by a deposition of gadolinium itself or by gadolinium-mediated changes, since histopathologic confirmation studies are not available yet. The hypothesis of gadolinium deposition exclusively caused by a linear GBCA, such as gadopentetate dimeglumine, is in line with theoretical considerations, as well as with findings from previous studies in which increased retention of a linear GBCA was reported in human bone, compared with a macrocyclic GBCA (7, 11, 12) .
In a study by Kasahara et al (13) , SI increase in the DN on nonenhanced T1-weighted images was described in patients treated with brain radiation. In contrast, neither whole-brain radiation nor tumor-selective radiation proved to be an independent confounder in our study. As noted by Errante et al (2) and Kanda et al (1) , the total number of enhanced MR imaging examinations was not considered among the clinical variables in the study of Kasahara et al (13) . Thus, the results of our study further support the theory that the reported SI increase on T1-weighted images by Kasahara et al (13) is caused by serial GBCA injections-frequently performed in patients after radiation therapy-rather than by the radiation therapy itself.
According to Errante et al (2) and contrary to Kanda et al (1), we excluded all patients with kidney dysfunction, NEURORADIOLOGY: Gadolinium Retention in the Dentate Nucleus and Globus Pallidus Radbruch et al determined by an eGFR of less than 60 mL/min per square meter, to reduce the potential confounding effect of this parameter. Since gadoterate meglumine and gadopentetate dimeglumine are both exclusively excreted by the kidney, liver dysfunction was not taken as an exclusion criterion. However, the regression analysis demonstrated that abnormal liver function did not have an influence on SI increase. Limitations of the current study are mostly caused by its retrospective design. Since patients were not randomly assigned to the different contrast agents, it cannot be ruled out that other confounding variables can explain the difference between the contrast agent groups; however, even when controlling for a large number of potentially confounding variables, the effect of the contrast agent group remained significant. Besides, the arbitrary number of six subsequent MR imaging examinations as an inclusion criterion was chosen to enable a comparison to the results of Kanda et al (1) , who had initially chosen this cutoff criterion. We cannot exclude any previous exposure to a GBCA in life prior to the first analyzed MR images in our department. Therefore, potential prolonged retention of the prior gadolinium application cannot be ruled out as a possible confounder. However, the relatively homogeneous patient groups in our study make this scenario highly unlikely.
Furthermore, an autopsy study showed evidence for gadolinium accumulation in the pons (although the accumulation in the pons was weaker compared with the DN, GP, and thalamus) (14) . To account for this, we repeated our analysis by using cerebellum and CSF as additional comparators. The results were comparable, although the differences between the two patient groups were largest when using the pons as comparator.
A further limitation of the study is that only two of the nine available GBCAs on the market have been analyzed. This approach was chosen because of the applied GBCAs in our department. Finally, we cannot exclude the fact that other properties of the assessed GBCAs besides the classification as either linear or macrocyclic contribute to the difference in SI increase. However, given the previously mentioned considerations about the different risk of gadolinium release for macrocyclic and linear GBCAs, taken together with the findings of Kanda et al (3) for the missing retention for the macrocyclic GBCA gadoteridol, this explanation seems highly likely. Future studies should include other GBCAs to finally solve this question.
As highlighted by Kanda et al (1), the mechanisms by which gadolinium causes SI increase in the DN remain unclear. Besides the retention of free gadolinium in the DN, a deposition of the entire molecule, including the complex, might be possible but unlikely, since the complex cannot cross an intact bloodbrain barrier. Also, gadolinium-induced cell changes or a gadolinium metabolism of the DN might be hypothesized. Future studies with histopathologic correlations should clarify the pathophysiological mechanism. Furthermore, it is still unclear whether the potential gadolinium retention is also present in other parts of the human body. For example, it was already shown in animal experiments that liver and bone might be primary repository organs for gadolinium (15, 16) .
Ultimately and most importantly, it is still unknown whether the reported SI increase does have any clinical correlates. This might be investigated within future studies by conducting a thorough clinical and radiologic examination of patients who already presented increased SI in the DN after serial GBCA applications.
In conclusion, high signal intensities in the DN and GP were associated exclusively with the linear GBCA gadopentetate dimeglumine but not with the macrocyclic GBCA gadoterate meglumine. Future studies should be conducted to investigate whether this difference holds true for all linear and macrocyclic GBCAs.
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